



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2020

Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help

Gargiulo, Giuseppe ; Goette, Andreas ; Vranckx, Pascal ; Valgimigli, Marco

Abstract: This commentary refers to ‘Appropriate cohort selection and its impact on a meta-analysis evaluating the efficacy of direct oral anticoagulants post-percutaneous coronary intervention’, by P. Agasthi-etal., 2020;41:1700.

DOI: <https://doi.org/10.1093/eurheartj/ehaa076>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-191740>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) License.

Originally published at:

Gargiulo, Giuseppe; Goette, Andreas; Vranckx, Pascal; Valgimigli, Marco (2020). Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. *European Heart Journal*, 41(17):1701-1702.

DOI: <https://doi.org/10.1093/eurheartj/ehaa076>

Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help

Giuseppe Gargiulo ¹, Andreas Goette^{2,3,4}, Pascal Vranckx⁵, and Marco Valgimigli ^{6*}

¹Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini 5, 80131 Naples, Italy; ²St. Vincenz-Hospital, Am Busdorf 2, 33098 Paderborn, Germany; ³Working Group of Molecular Electrophysiology, University Hospital Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany; ⁴Atrial Fibrillation Network (AFNET), Mendel Str. 11, 48149 Münster, Germany; ⁵Department of Cardiology and Intensive Care Medicine, Jessa Ziekenhuis, Faculty of Medicine and Life Sciences at the Hasselt University, Stadsomvaart 11, 3500 Hasselt, Belgium; and ⁶Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010 Bern, Switzerland

Online publish-ahead-of-print 14 February 2020

This commentary refers to ‘Appropriate cohort selection and its impact on a meta-analysis evaluating the efficacy of direct oral anticoagulants post-percutaneous coronary intervention’, by P. Agasthi et al., 2020;41:1700.

We thank Dr Agasthi and colleagues for their interest in our meta-analysis^{1,2} and for drawing our attention to the finding that double antithrombotic therapy with direct oral anticoagulants (DOAC-DAT) is associated to an increased risk of stent thrombosis (ST) as compared to triple antithrombotic therapy with vitamin K antagonists. Their argumentations are two-fold:

- (1) We included all patients participating in the AUGUSTUS study irrespective of whether they received percutaneous coronary intervention (PCI) at index event.
- (2) A signal suggesting higher ST risk was observed with dabigatran 110 mg but less so with dabigatran 150 mg within the RE-DUAL PCI study.

The rationale for including all study participants and not just those who received PCI shortly before study inclusion arises from the need to respect the randomization process, while avoiding arbitrary selection of a post-randomization subgroup for which randomization was not stratified for. It is noteworthy emphasizing that even patients who did not receive PCI or stent implantation at the time of qualifying event were exposed to the risk of ST because of stent-assisted procedure performed in the past. Indeed, two of the overall 32 definite/probable ST cases observed during the study occurred in patients allocated to DAT who received stent implantation prior to but not at the time of qualifying event. Restricting the analysis to patients within the AUGUSTUS trial

who had stent implantation at the time of qualifying event yields entirely consistent results with respect to the pooled relative risk increase for the endpoint definite/probable ST with DOAC-DAT, with 80% of the events occurring within 30 days from randomization as recently published.³

An arbitrary selection of patients who received only one of the two tested dabigatran doses within the RE-DUAL PCI trial would even be more questionable. All patients in the USA and non-elderly patients in other countries were randomly assigned to the 110-mg DAT group, the 150-mg DAT group, or the TAT group in a 1:1:1 ratio. Elderly patients outside the USA were randomly assigned to the 110-mg DAT group or the TAT group in a 1:1 ratio; they were not eligible to be assigned to the 150-mg DAT group, in accordance with the recommendations of the dabigatran label in those countries. Based on this asymmetric randomization process and limited statistical power, the statistical analysis plan of the trial pre-specified that both dabigatran doses had to be analysed together and contrasted with TAT. As such, the observation that numerical higher rates of ST occurred mainly in patients taking the low but not the high dabigatran regimen can be subject to a considerable play of chance. Finally, a numerical excess of ST occurred in the DOAC-DAT arm of the AUGUSTUS trial despite the use of apixaban at full and approved regimen for stroke prevention (i.e. 5 mg b.i.d.). Hence, whether the use of a full non-vitamin K antagonist oral anticoagulant regimen helps mitigate the ST risk observed consistently across all DOAC-DAT trials remains currently speculative.

We therefore stand with our prior conclusion and believe that the higher risk of ST is real as it comes consistently across all included studies without heterogeneity.

* Corresponding author. Tel: +41 31 632 96 53, Fax: +41 31 632 47 71, Email: marco.valgimigli@insel.ch

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Conflict of interest: A.G. discloses honoraria and speaker fees from Astra Zeneca, Bayer Health Care, Berlin-Chemie, Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Medtronic, Novartis, and Omeicos. Research has been supported by Josef-Freitag Stiftung and Deutsche Herzstiftung E.V. outside the submitted work. P.V. discloses personal fees from Daiichi Sankyo, AstraZeneca, Bayer Health Care, and Terumo outside the submitted work. M.V. reports grants and personal fees from Abbott, Alvimedica, Amgen, Bayer, Bristol-Myers Squibb SA, Coreflow, Daiichi Sankyo, Vifor, Idorsia, Terumo, and iVascular; grants and personal fees from grants from AstraZeneca and Medicure, outside the submitted work. G.G. has nothing to disclose.

References



1. Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. *Eur Heart J* 2019;**40**:3757–3767.
2. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, Vinereanu D, Granger CB, Goodman SG, Aronson R, Windecker S, Thiele H, Valgimigli M, Mehran R, Alexander JH. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. *Circulation* 2019;doi: 10.1161/CIRCULATIONAHA.119.044584.
3. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimtz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. *Lancet* 2019;**394**: 1335–1343.

CARDIOVASCULAR FLASHLIGHT

doi:10.1093/eurheartj/ehz796

Online publish-ahead-of-print 7 November 2019

Vasospastic angina following immune checkpoint blockade

Kazuya Otsu, Kazuko Tajiri , Shunsuke Sakai , and Masaki Ieda 

Department of Cardiology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan

* Corresponding author. Tel: +81-29-853-3143, Fax: +81-29-853-3227, Email: ktajiri@md.tsukuba.ac.jp

A 57-year-old man had renal cell carcinoma with lung and bone metastases and had undergone 2 cycles of anticancer treatment with an immune checkpoint inhibitor, nivolumab (3 mg/kg, every 2 weeks). Two weeks after the last administration of nivolumab, he was admitted to our hospital due to several episodes of rest angina, especially at night and in the early morning. Resting chest pain, which lasted for 5–20 min, appeared 3 days after the first nivolumab administration and gradually worsened. He had no history of heart disease. Previous management of his renal cell carcinoma involved chemotherapy with sunitinib and axitinib. He had never received radiation therapy to his chest. After admission, he had spontaneous episodes of rest angina with transient ischaemic electrocardiographic (ECG) changes that promptly resolved with nitrate. He underwent coronary angiography 3 days after admission. Immediately after entering the catheterization laboratory, he complained of chest pain, and his ECG showed ST depression in multiple leads (*Panel A*). Coronary angiography revealed multiple spasms throughout the coronary bed (*Panel B*), which was resolved after intracoronary nitroglycerine administration (*Panel C*). He was diagnosed with vasospastic angina, and the symptoms disappeared gradually with the up-titration of a calcium channel blocker and a nitrate. He was able to continue nivolumab treatment without recurring chest pain under coronary vasodilator medication.

In summary, this is a rare case of vasospastic angina following immune checkpoint blockade. Cardiologists and oncologists should be vigilant for vasospasm as a possible immune-related adverse event.

